In particular, EBV+ lymphoproliferative disorders have been seen in patients on methotrexate, tumor necrosis factor (TNF)α inhibitors, fludarabine and mycofenolate mofetil (75–78). This evidence concerns the gene TNF and lymphoproliferative syndrome.